Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;27(9S Suppl 5):S20-S22.
doi: 10.1097/IGC.0000000000001118.

Ovarian Cancer Prevention, Screening, and Early Detection: Report From the 11th Biennial Ovarian Cancer Research Symposium

Jeremy Chien, Elizabeth M Poole

Ovarian Cancer Prevention, Screening, and Early Detection: Report From the 11th Biennial Ovarian Cancer Research Symposium

Jeremy Chien et al. Int J Gynecol Cancer. 2017 Nov.

Abstract

Objective: The aim of this study is to provide a summary report on recent research advances in ovarian cancer prevention, screening, and early detection that were presented at the 11th Biennial Ovarian Cancer Research Symposium in Seattle, Wash.

Methods: At the symposium, researchers from around the world participated in the poster, invited oral presentation and keynote presentation, and discussed the latest advances in the areas of cancer prevention, screening, and early detection.

Results: In the Scientific Session for Prevention, Screening, and Early Detection, Usha Menon, PhD (University of College London), presented exploratory studies from the ongoing UK Collaborative Trial of Ovarian Cancer Screening trial. Karen Lu, MD, presented her studies on BRCA testing and salpingectomies as prevention strategies. Eight speakers were selected from the abstracts for short oral presentations, and the topic ranges from Ovarian Cancer Early Detection Program by Saul Rivkin, MD, to the ultra-deep sequencing of somatic mutations in TP53 in normal and cancer patients by Rosana Risques, PhD. Fourteen additional poster presentations, ranging from the potential role of cancer stem cells in recurrence to retrotransposons in ovarian cancer development, round up the session.

Conclusions: Although progress is being made in the areas of prevention, screening, and early detection, these advances have not yet translated into tangible clinical benefits for patients with ovarian cancer. A wide array of research topics presented in the session provides a glimmer of hope that better understanding of genetic risk factors, refining screening strategies, and developing new methods for early detection will eventually lead to improved outcome for patients with ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report.

References

    1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384: 1376–88. - PubMed
    1. Ledermann JA, Raja FA, Fotopoulou C et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6: vi24–32. - PubMed
    1. SEER Cancer Statistics Review, 1975–2013. In: H N, N AM, K M et al., eds. National Cancer Institute; 2016.
    1. 11th Biennial Ovarian Cancer Research Symposium Ovarian Cancer Research Symposium at the Rivkin Center for Ovarian Cancer; (2016) June 2017; Seattle, Washington: AACR Publications; (2016).
    1. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA : the journal of the American Medical Association. 2011;305: 2295–303. - PubMed

Publication types